NN3206
/ Novelty Nobility
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 25, 2025
KOAS seeks to acquire antibody drug developer Novelty Nobility
(Korea Biomedical Review)
- "KOAS has decided to invest 50 billion won ($36 million) in Novelty Nobility through new funding from institutional investors....Novelty Nobility has two pipelines, NN3201 and NN3206, which apply unique next-generation payloads."
M&A • Solid Tumor
1 to 1
Of
1
Go to page
1